Research on immunotherapy for glioblastoma is ongoing, with studies exploring various approaches to overcome resistance and improve treatment outcomes. These approaches include the development of new biologics, vaccine strategies, and biomaterials, as well as the identification of biomarkers to predict treatment response. The field appears to be at a crossroads, with multiple potential therapeutic horizons and ongoing clinical trials investigating combination therapies.